Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
19.96
+0.56 (2.89%)
At close: Jun 26, 2026, 4:00 PM EDT
19.87
-0.09 (-0.45%)
After-hours: Jun 26, 2026, 7:57 PM EDT
Immunome Employees
Immunome had 177 employees as of December 31, 2025. The number of employees increased by 59 or 50.00% compared to the previous year.
Employees
177
Change (1Y)
59
Growth (1Y)
50.00%
Revenue / Employee
$19,490
Profits / Employee
-$1,090,257
Market Cap
2.26B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Agios Pharmaceuticals | 540 |
| Vericel | 398 |
| Intellia Therapeutics | 377 |
| Ocular Therapeutix | 325 |
| Nuvation Bio | 307 |
| Biohaven | 274 |
| Pharvaris | 134 |
| Kodiak Sciences | 130 |
IMNM News
- 15 days ago - Immunome announces first patient dosed in Phase 1 trial of IM-1617 - TheFly
- 16 days ago - Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors - Business Wire
- 17 days ago - Immunome Transcript: AGM 2026 - Transcripts
- 17 days ago - Immunome Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 22 days ago - Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 26 days ago - Immunome announces Ringside trial met primary, secondary endpoints - TheFly
- 27 days ago - Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting - Business Wire
- 4 weeks ago - Immunome Slides: Investor presentation - Filings